Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06321575

The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)

Led by Avantec Vascular · Updated on 2026-02-10

159

Participants Needed

20

Research Sites

123 weeks

Total Duration

On this page

Sponsors

A

Avantec Vascular

Lead Sponsor

B

Bright Research Partners

Collaborating Sponsor

AI-Summary

What this Trial Is About

The objective of this study is to establish reasonable assurance of safety and effectiveness of the Golazo® Peripheral Atherectomy System when used as indicated in 159 subjects with symptomatic infrainguinal peripheral arterial disease (PAD) in up to 20 investigational sites in the U.S.

CONDITIONS

Official Title

The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Candidate for atherectomy of the peripheral vasculature in the lower limbs
  • Life expectancy greater than 1 year as judged by the investigator
  • Resting ankle brachial index (ABI) of 0.90 or less, or 0.75 or less after exercise; toe brachial index (TBI) if arteries are non-compressible
  • Target limb Rutherford clinical classification category 3 to 5
  • Suitable candidate for angiography and endovascular intervention as judged by the investigator
  • Willing and able to comply with study procedures and assessments
  • Signed informed consent
  • Target lesion(s) with 70% or greater stenosis by angiographic visual estimation
  • Total treated lesion length 20 cm or less by angiographic visual estimation
  • Target vessel diameter between 2.0 mm and 4.5 mm by angiographic visual estimation
  • Target limb has at least one patent below the knee vessel crossing the ankle providing foot perfusion at baseline
Not Eligible

You will not qualify if you...

  • Active infection in the target limb
  • History of endovascular or open vascular surgery on the target limb within the last 30 days
  • Planned surgical or interventional procedure within 30 days after the index procedure
  • Lesion in the opposite limb requiring intervention during or within 30 days after the procedure
  • Critical limb ischemia with Rutherford category 6
  • Significant kidney disease with GFR less than 30 or requiring dialysis
  • Acute myocardial infarction or uncontrolled comorbidity as judged by investigator
  • Myocardial infarction or stroke within 2 months before screening
  • Pregnant or breastfeeding
  • Participation in another clinical study with incomplete treatment or conflicting endpoints
  • Contraindications to antiplatelet, anticoagulant, or thrombolytic therapy
  • Uncorrectable bleeding disorders, platelet dysfunction, thrombocytopenia below 125,000/microliter, or INR above 1.5
  • Allergy to contrast agents or medications used in endovascular intervention that cannot be treated
  • History of heparin-induced thrombocytopenia
  • Thrombolytic therapy within 2 weeks before enrollment
  • Target lesion within a native or synthetic graft
  • Untreated significant stenosis or occlusion of inflow vessels
  • History or evidence of intracranial or gastrointestinal bleeding or aneurysm
  • Vulnerable populations such as incarcerated or cognitively challenged adults
  • Foot complications including osteomyelitis extending to metatarsal bones, gangrene of plantar skin, deep or large ulcers over 3 cm on plantar skin, heel ulcers with or without bone involvement, wounds requiring flap coverage, neuropathic or non-ischemic wounds
  • Congestive heart failure with NYHA class III or higher
  • More than 2 lesions to be treated or lesions within 3 mm not considered as single tandem lesion
  • Clinical or angiographic complications related to other devices prior to investigational device use
  • In-stent restenosis within target lesion(s)
  • Unstable or flow-limiting dissections type C or greater
  • Evidence of distal embolization
  • Inability to cross the lesion with a guidewire

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 20 locations

1

HonorHealth Scottsdale Osborn Medical Center

Scottsdale, Arizona, United States, 85251

Actively Recruiting

2

Pulse Cardiovascular Institute

Scottsdale, Arizona, United States, 85251

Actively Recruiting

3

Merced Vascular

Merced, California, United States, 95340

Actively Recruiting

4

Palm Vascular Center

Fort Lauderdale, Florida, United States, 33312

Actively Recruiting

5

First Coast Cardiovascular Institute

Jacksonville, Florida, United States, 32256

Actively Recruiting

6

Radiology and Imaging Specialists of Lakeland

Lakeland, Florida, United States, 33801

Completed

7

Amavita Research Services

Miami, Florida, United States, 33137

Actively Recruiting

8

Cardiovascular Consultants of South Georgia

Thomasville, Georgia, United States, 31792

Actively Recruiting

9

Pacific Vascular Institute

‘Aiea, Hawaii, United States, 96701

Actively Recruiting

10

Baton Rouge General Hospital

Baton Rouge, Louisiana, United States, 70809

Actively Recruiting

11

Cardiovascular Institute of the South - Houma

Houma, Louisiana, United States, 70360

Actively Recruiting

12

Cardiovascular Institute of the South - Lafayette

Lafayette, Louisiana, United States, 70506

Actively Recruiting

13

Vascular Breakthroughs

Plymouth, Massachusetts, United States, 02360

Actively Recruiting

14

Advanced Heart and Vascular Institute

Flemington, New Jersey, United States, 08822

Actively Recruiting

15

Spartanburg Regional Medical Center

Spartanburg, South Carolina, United States, 29303

Actively Recruiting

16

Tennessee Center for Clinical Trials

Tullahoma, Tennessee, United States, 37388

Actively Recruiting

17

Nextstage Clinical Research - Beaumont

Beaumont, Texas, United States, 77702

Actively Recruiting

18

Hope Vascular & Podiatry

Houston, Texas, United States, 77054

Actively Recruiting

19

Nextstage Clinical Research - Waco

Waco, Texas, United States, 76712

Actively Recruiting

20

Bellin Health

Green Bay, Wisconsin, United States, 54301

Actively Recruiting

Loading map...

Research Team

G

Gene Reu

CONTACT

J

Jessi Maumee

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here